Thyroid nodules
Appearance
A discrete lesion within the thyroid gland
- Remains a clinical problem to identify which tumours are at risk of causing actual harm to patients if left untreated, and balancing risk of intervention with small risk of the watch-and-wait approach.
- Approach:
- USS for TI-RADS
- FNA for Bethesda
- Discharge/surveillance/surgery based on Bethesda
Epidemiology
[edit | edit source]- In iodine-replete areas:
- 20-65% of patients will have some sort of nodule if you ultrasound them
- 5% of women and 1% of men will have a palpable thyroid nodule
- 5-10% of nodules will be malignant, but the vast majority do not require surgical intervention
- Diagnosis of thyroid nodules has increased dramatically over the past 30 years, mostly due to the increased pickup rate of <1cm PTCs (microcarcinomas).
- No change in mortality rate
Risk factors for cancer:
[edit | edit source]- History
- Rapid growth
- First-degree relative with thyroid cancer
- Head and neck radiation - takes between 6-35 years to develop into cancer
- Total body irradiation
- Thyroid cancer syndromes e.g. MEN-2, FAP, Cowden's disease
- Young patient <20yo - think medullary cancer, but not necessarily likely to be that
- Age >70yo
- Male sex
- Exam:
- Fixed, hard mass
- Obstructive symptoms
- Vocal cord paralysis
- Nodules >3-4cm
Pathophysiology
[edit | edit source]- Colloid nodules
- Degenerative cysts
- Nodular hyperplasia
- Follicular or Hurthle cell adenomas
- Malignancies - see separate topic
Presentation
[edit | edit source]- Majority benign and asymptomatic
- Consider features of hyper-functioning/toxic nodule (hyperthyroidism - see separate topic)
Initial investigation
[edit | edit source]- TFTs: TSH, T3/T4
- Calcium, PTH, vitamin D
- Optional: (mostly if TSH is abnormal)
- TRABS - exclude Graves disease
- Anti-TPO Ab - Hashimoto's
- Thyroid antibodies
- Calcitonin - only if suspected medullary cancer
- Genetic testing - e.g. BRAF
Imaging:
[edit | edit source]- USS first-line:
- Nodules picked up on examination
- Incidental nodules found through other modalities
- CT to evaluate for retrosternal extension or metastases - don't generally give IV contrast, since it will preclude the ability to give radioactive iodine
- Nuclear medicine thyroid scintigraphy
- Indication - hyperthyroidism and thyroid nodule
- Looking for a toxic nodule
- Incidental PET-positive nodule has quite a high rate of malignancy - exact number varies from study to study - could say 40%
- Have a lower threshold to biopsy rather than purely following TIRADS
- ATA guidelines suggest biopsy anything PET-positive >1cm (equivalent to TR5). They will almost always be >1cm to show up on PET anyway.
- Differentials: colloid nodule, follicular adenomas (functioning and non-functioning), MNG, nodular thyroiditis (subacute and chronic lymphocytic), degenerative thyroid cyst, malignancy, parathyroid, lipoma, paraganglioma, very rarely infiltrative disorders (e.g. haemochromatosis)
Ultrasound findings:
- Look at: (those in bold have higher specificity for cancer)
- Echogenicity (hypoechoic is suspicious)
- Calcifications and microcalcifications
- Shape (taller than wide, with irregular margins - since malignancies tend to cross tissue planes)
- Vascularity
- Composition
- Nodes
- Reassuring for benign - spongiform pattern, purely cystic appearance
- Elastography (measuring stiffness of thyroid nodule using USS) is not currently recommended for routine use
TI-RADS:
| Composition | Echogenicity | Shape | Margin | Echogenic foci | |||||
| Cystic or almost completely cystic | 0 | Anechoic | 0 | Wider-than-tall | 0 | Smooth | 0 | None or large comet-tail artifacts | 0 |
| Spongiform | 0 | Hyperechoic or isoechoic | 1 | Taller-than-wide | 3 | Ill-defined | 0 | Macrocalcifications | 1 |
| Mixed cystic and solid | 1 | Hypoechoic | 2 | Lobulated or irregular | 2 | Peripheral (rim) calcifications | 2 | ||
| Solid or almost completely solid | 2 | Very hypoechoic | 3 | Extrathyroidal extension | 3 | Punctate echogenic foci | 3 |
| Points | Malignancy risk (%) | Biopsy threshold (mm) | |
| TR1 | 0 | 0.3 | No biopsy |
| TR2 | 2 | 1.5 | No biopsy |
| TR3 | 3 | 4.8 | 25 |
| TR4 | 4 to 6 | 9.1 | 15 |
| TR5 | 7+ | 35.0 | 10 |
ATA:
Can use ATA score or TI-RADS for risk-stratifying thyroid nodules. Both independently validated but TI-RADS currently thought to be better.
- These will decide whether or not to proceed with FNA
- Also incorporate clinical assessment - FNA can still be considered in nodules <1cm or not otherwise meeting criteria with:
- Strong family history thyroid cancer
- Young patient
- Therapeutic head and neck radiation
- Preference for FNA over observation
- Location of nodule in thyroid
- Lymphadenopathy
- Immobile, fixed mass with voice changes
Cytopathological risk stratification
[edit | edit source]- FNA is preferred technique - gives good enough answer to render larger biopsies such as CNB obsolete, unless lymphoma is a high possibility
- Can technically be done blind, but USS-guided is obviously better
- Mean sensitivity >80%, mean specificity >90%
- 23-27-gauge needle
- Confirm adequacy of specimen at time of biopsy (6 groups of well-visualised follicular cells, 10 cells per group)
- Contraindications to FNA:
- Prohibitive surgical risk
- Already proceeding with thyroidectomy
- Extreme elderly with small nodules
- Use BETHESDA system for thyroid cytopathology (last updated 2017; below)
- Categories 2 and 6 are highly accurate, with error rate <3%
- Others quite variable - see ranges of malignancy below
- Traditional recommendation for 3 and 4 lesions to have lobectomy, but efforts now to reduce that rate, since most are benign. Molecular testing may help.
- Molecular testing
- Complex field. Tests can be considered as either 'rule-in' or 'rule-out' tests.
- Most useful for Bethesda 3 and 4 nodules
- Take into account the holistic picture and order appropriately.
- Afirma Gene Expression Classifier - mostly rule-out - 90% sensitivity, but specificity 50% for Bethesda 3 and 4 nodules
- Afirma Genomic Sequence Classifier - se 91% sp 68%. Particularly poor performance for Hurthle cell adenoma and carcinoma.
- ThyroSeq v2 - se >90% sp >90% in early studies, but subsequent validation outcomes were poor.
- ThyroSeq v3 - se 94% sp 82% in Bethesda 3 + 4, and better performance in Hurthle cell. Costs about $2,100 per nodule in Australia, with no medicare rebate, and takes a couple of weeks.
| Bethesda class | Diagnostic category | Cancer risk |
| I | Nondiagnostic (unsatisfactory) | 5 to 10% |
| II | Benign | 0 to 3% |
| III | Atypia of undetermined significance (AUS) or follicular lesion of undetermined significance (FLUS) | 10 to 30% |
| IV | Follicular neoplasm (or suspicious for follicular neoplasm, also encompassing Hurthle cell neoplasm) | 25 to 40% |
| V | Suspicious for malignancy | 50 to 75% |
| VI | Malignant | 97 to 99% |
- Repeat FNA, then excisional biopsy if still indeterminate
- Some surgeons say 2x FNA then 1x core biopsy then consider excision
- Repeat follow-up 2-3 years is probably standard for these nodules
- Cancer risk is overstated for this group. Consider clinical and radiographical factors (as in, were you expecting a higher Bethesda score based on the TI-RADS?). Consider repeat FNAB or lobectomy.
- Typically excised. Mostly found to be follicular adenomas or adenomatoid nodules of MNG. Can't tell the difference between benign and malignant follicular lesions on FNA - need to see whether there is capsular invasion.
- Surgical resection
- Surgical resection, unless widely metastatic.
Management options
[edit | edit source]- Discharge
- Surveillance
- Surgery
Management of thyroid nodules in pregnancy
[edit | edit source]- If symptomatic of severe compression - immediate surgery
- If asymptomatic, USS and FNA as usual
- Well-differentiated cancer could have second trimester surgery or defer until post-partum, depending on risk profile
- Anaplastic or MTC would generally have immediate surgery
- Suspicious FNA could either have second-trimester surgery or deferred workup
Follow-up for nodules that don't meet FNA criteria/benign
[edit | edit source]- <1cm with suspicious characteristics: 6-12 months
- Low-intermediate suspicion on USS - 12-24 months
- Very low-risk nodules: 2-3 years
- Benign: 1-3 years depending on risk factors
- 2x FNAs with both benign: No further USS indicated
Surgery
[edit | edit source]- Indications for surgery:
- Concern for malignancy
- Hyperfunction
- Local compressive symptoms
- Lobectomy vs thyroidectomy (ATA guidelines 2016)
- >4cm differentiated cancer: total thyroidectomy
- 1-4cm without clinical evidence of extrathyroidal disease or nodal mets or high-risk features: Either total thyroidectomy or lobectomy are appropriate. Controversial.
- <1cm: surveillance or lobectomy
- Favour total thyroidectomy in
- Age >45
- Contralateral thyroid nodules
- Hx radiation exposure
- Familial DTC
- Patient preference
Follow-up post-op:
[edit | edit source]- Note that following lobectomy, if pathology is malignant, TSH will need to be maintained <2mIU/L